Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease-a long-term follow-up

Molecular Genetics and Metabolism

Volumn 112, Issue 1, 2014, Pages 40-43

  Andreassen, Christer Swan ^a,b   Schlütter, Jacob Mørup ^a   Vissing, John ^c   Andersen, Henning ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Enzyme replacement therapy; Late onset pompe disease; Muscle strength; Muscle volume; Respiratory function; Walking capacity

Indexed keywords

RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE; GAA PROTEIN, HUMAN;

ADULT; ARTICLE; CASE REPORT; DISEASE DURATION; DYNAMOMETRY; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; EVALUATION AND FOLLOW UP; EXTENSOR MUSCLE; FEMALE; FLEXOR MUSCLE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; MALE; MUSCLE ISOMETRIC CONTRACTION; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANGE OF MOTION; THERAPY EFFECT; VITAL CAPACITY; WALKING; DRUG EFFECTS; FOLLOW UP; GLYCOGEN STORAGE DISEASE TYPE II; MIDDLE AGED; MOTOR PERFORMANCE; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

ADULT; ALPHA-GLUCOSIDASES; ENZYME REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MALE; MIDDLE AGED; MOTOR SKILLS; MUSCLE STRENGTH; MUSCLE, SKELETAL;

EID: 84899627455     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2014.02.015     Document Type: Article

References (17)

1. Laforet P., Nicolino M., Eymard P.B., Puech J.P., Caillaud C., Poenaru L., Fardeau M. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 2000, 55:1122-1128.
2. Hagemans M.L., Winkel L.P., Van Doorn P.A., Hop W.J., Loonen M.C., Reuser A.J., Van der Ploeg A.T. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005, 128:671-677.
3. Muller-Felber W., Horvath R., Gempel K., Podskarbi T., Shin Y., Pongratz D., Walter M.C., Baethmann M., Schlotter-Weigel B., Lochmuller H., Schoser B. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul. Disord. 2007, 17:698-706.
4. Wokke J.H., Escolar D.M., Pestronk A., Jaffe K.M., Carter G.T., van den Berg L.H., Florence J.M., Mayhew J., Skrinar A., Corzo D., Laforet P. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2008, 38:1236-1245.
5. van der Ploeg A.T., Clemens P.R., Corzo D., Escolar D.M., Florence J., Groeneveld G.J., Herson S., Kishnani P.S., Laforet P., Lake S.L., Lange D.J., Leshner R.T., Mayhew J.E., Morgan C., Nozaki K., Park D.J., Pestronk A., Rosenbloom B., Skrinar A., van Capelle C.I., van der Beek N.A., Wasserstein M., Zivkovic S.A. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N. Engl. J. Med. 2010, 362:1396-1406.
6. Ravaglia S., Pichiecchio A., Ponzio M., Danesino C., Saeidi Garaghani K., Poloni G.U., Toscano A., Moglia A., Carlucci A., Bini P., Ceroni M., Bastianello S. Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response. J. Inherit. Metab. Dis. 2010, 33:737-745.
7. Walton J., Rowland L. Clinical examination, differential diagnosis and classification. Disorders of Voluntary Muscle 1994, 1771. Churchill Livingstone, New York. J. Walton, G. Karpati, D. Hilton-Jones (Eds.).
8. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., Yernault J.C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur. Respir. J. Suppl. 1993, 16:5-40.
9. Harbo T., Brincks J., Andersen H. Maximal isokinetic and isometric muscle strength of major muscle groups related to age, body mass, height, and sex in 178 healthy subjects. Eur. J. Appl. Physiol. 2012, 112:267-275.
10. Andreassen C.S., Jakobsen J., Ringgaard S., Ejskjaer N., Andersen H. Accelerated atrophy of lower leg and foot muscles-a follow-up study of long-term diabetic polyneuropathy using magnetic resonance imaging (MRI). Diabetologia 2009, 52:1182-1191.
11. Toscano A., Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J. Neurol. 2013, 260:951-959.
12. van der Ploeg A.T., Barohn R., Carlson L., Charrow J., Clemens P.R., Hopkin R.J., Kishnani P.S., Laforet P., Morgan C., Nations S., Pestronk A., Plotkin H., Rosenbloom B.E., Sims K.B., Tsao E. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol. Genet. Metab. 2012, 107:456-461.
13. Raben N., Fukuda T., Gilbert A.L., de Jong D., Thurberg B.L., Mattaliano R.J., Meikle P., Hopwood J.J., Nagashima K., Nagaraju K., Plotz P.H. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol. Ther. 2005, 11:48-56.
14. Drost M.R., Schaart G., van Dijk P., van Capelle C.I., van der Vusse G.J., Delhaas T., van der Ploeg A.T., Reuser A.J. Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease. Muscle Nerve 2008, 37:251-255.
15. Johnson M.A., Polgar J., Weightman D., Appleton D. Data on the distribution of fibre types in thirty-six human muscles. An autopsy study. J. Neurol. Sci. 1973, 18:111-129.
16. Edgerton V.R., Smith J.L., Simpson D.R. Muscle fibre type populations of human leg muscles. Histochem. J. 1975, 7:259-266.
17. Green H.J., Daub B., Houston M.E., Thomson J.A., Fraser I., Ranney D. Human vastus lateralis and gastrocnemius muscles. A comparative histochemical and biochemical analysis. J. Neurol. Sci. 1981, 52:201-210.